{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:47:32Z","timestamp":1792064852486,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Technology Assessment"},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS) is a chronic, painful disease affecting flexures and other skin regions, producing nodules, abscesses and skin tunnels. Laser treatment targeting hair follicles and deroofing of skin tunnels are standard HS interventions in some countries but are rarely offered in the UK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe current UK HS management pathways and influencing factors to inform the design of future randomized controlled trials (RCTs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>THESEUS was a nonrandomized 12-month prospective cohort study set in 10 UK hospitals offering five interventions: oral doxycycline 200\u2005mg daily; oral clindamycin and rifampicin both 300\u2005mg twice daily for 10 weeks, extended for longer in some cases; laser treatment targeting hair follicles; deroofing; and conventional surgery. The primary outcome was the combination of clinician-assessed eligibility and participant hypothetical willingness to receive each intervention. The secondary outcomes were the proportion of participants selecting each intervention as their final treatment option; the proportion who switch treatments; treatment fidelity; and attrition rates. THESEUS was prospectively registered on the ISRCTN registry: ISRCTN69985145.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The recruitment target of 150 participants was met after 18\u2005months, in July 2021, with two pauses due to the COVID-19 pandemic. Baseline demographics reflected the HS secondary care population: average age 36\u2005years, 81% female, 20% non-White, 64% current or ex-smokers, 86% body mass index \u2265 25, 68% with moderate disease, 19% with severe disease and 13% with mild disease. Laser was the intervention with the highest proportion (69%) of participants eligible and willing to receive treatment, then deroofing (58%), conventional surgery (54%), clindamycin and rifampicin (44%), and doxycycline (37%). Laser was ranked first choice by the greatest proportion of participants (41%). Attrition rates were 11% and 17% after 3 and 6\u2005months, respectively. Concordance with doxycycline was 52% after 3\u2005months due to lack of efficacy, participant choice and adverse effects. Delays with procedural interventions were common, with only 43% and 26% of participants starting laser and deroofing, respectively, after 3\u2005months. Uptake of conventional surgery was too small to characterize the intervention. Switching treatment was uncommon and there were no serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>THESEUS has established laser treatment and deroofing for HS in the UK and demonstrated their popularity with patients and clinicians for future RCTs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad388","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T10:10:54Z","timestamp":1697105454000},"page":"382-391","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Hidradenitis Suppurativa Evaluation Study\u00a0(THESEUS): a prospective cohort study"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"first","affiliation":[{"name":"Division of Infection & Immunity"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-2415","authenticated-orcid":false,"given":"Janine","family":"Bates","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5235-6517","authenticated-orcid":false,"given":"Rebecca","family":"Cannings-John","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9170","authenticated-orcid":false,"given":"Fiona","family":"Collier","sequence":"additional","affiliation":[{"name":"NHS Forth Valley , Stirling, Scotland , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Evans","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-4954","authenticated-orcid":false,"given":"Angela","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Public contributors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0462-7789","authenticated-orcid":false,"given":"Ceri","family":"Harris","sequence":"additional","affiliation":[{"name":"Public contributors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-7394","authenticated-orcid":false,"given":"Laura","family":"Howells","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham , Nottingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-8631","authenticated-orcid":false,"given":"Kerenza","family":"Hood","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6120-8433","authenticated-orcid":false,"given":"Rachel","family":"Howes","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, John Radcliffe Hospital, Oxford NHS Trust , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-0274","authenticated-orcid":false,"given":"Paul","family":"Leighton","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham , Nottingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5512-1745","authenticated-orcid":false,"given":"Muhammad","family":"Riaz","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-5026","authenticated-orcid":false,"given":"Jeremy","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Stoke Mandeville Hospital, Buckinghamshire Healthcare Trust , Aylesbury , UK"},{"name":"Warwick Clinical Trials Unit, University of Warwick , Warwick , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-3667","authenticated-orcid":false,"given":"Helen","family":"Stanton","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-7465","authenticated-orcid":false,"given":"Kim S","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham , Nottingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-2786","authenticated-orcid":false,"given":"Emma","family":"Thomas-Jones","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"2024021708482933700_ljad388-B1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024021708482933700_ljad388-B2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/jamadermatol.2020.5467","article-title":"Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary","volume":"157","author":"Frew","year":"2021","journal-title":"JAMA Dermatology"},{"key":"2024021708482933700_ljad388-B3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surgery"},{"key":"2024021708482933700_ljad388-B4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jamadermatol.2017.0432","article-title":"Interventions for hidradenitis suppurativa updated summary of an original Cochrane review","volume":"153","author":"Ingram","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2024021708482933700_ljad388-B5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024021708482933700_ljad388-B7","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/bjd.13163","article-title":"The hidradenitis suppurativa priority setting partnership","volume":"171","author":"Ingram","year":"2014","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1524-4725.2009.01214.x","article-title":"Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser","volume":"35","author":"Tierney","year":"2009","journal-title":"Dermatol Surg"},{"key":"2024021708482933700_ljad388-B9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2020.04.117","article-title":"Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium-garnet laser: a multicenter, prospective, randomized, intraindividual, comparative trial","volume":"84","author":"Naouri","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024021708482933700_ljad388-B10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaad.2009.12.018","article-title":"Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions","volume":"63","author":"van der Zee","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2024021708482933700_ljad388-B11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/bjd.19302","article-title":"What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?","volume":"183","author":"Hasan","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bjps.2021.08.038","article-title":"The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study","volume":"75","author":"Howes","year":"2022","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2024021708482933700_ljad388-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3399\/BJGPO.2021.0051","article-title":"Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs","volume":"5","author":"Collier","year":"2021","journal-title":"BJGP Open"},{"key":"2024021708482933700_ljad388-B14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/bjd\/ljad152","article-title":"Research priorities in the management of hidradenitis suppurativa","volume":"189","author":"Leighton","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B15","doi-asserted-by":"crossref","first-page":"e060815","DOI":"10.1136\/bmjopen-2022-060815","article-title":"Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study","volume":"12","author":"Bates","year":"2022","journal-title":"BMJ Open"},{"key":"2024021708482933700_ljad388-B16","author":"Centre for Trials Research"},{"key":"2024021708482933700_ljad388-B17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group","volume":"97","author":"Horvath","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2024021708482933700_ljad388-B18","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B19","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjd.19344","article-title":"Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa","volume":"184","author":"Kirby","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024021708482933700_ljad388-B23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"2024021708482933700_ljad388-B24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u00a0\u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2024021708482933700_ljad388-B25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/bjs.10115","article-title":"Practical guide to the Idea, Development and Exploration stages of the IDEAL framework and recommendations","volume":"103","author":"Pennell","year":"2016","journal-title":"Br J Surg"},{"key":"2024021708482933700_ljad388-B26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"2024021708482933700_ljad388-B27","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"2024021708482933700_ljad388-B28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024021708482933700_ljad388-B29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","article-title":"The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study","volume":"85","author":"van Straalen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024021708482933700_ljad388-B30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2024021708482933700_ljad388-B31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1684\/ejd.2020.3920","article-title":"Intense pulsed light treatment for hidradenitis suppurativa: a within-person randomized controlled trial","volume":"30","author":"Andersen","year":"2020","journal-title":"Eur J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad388\/54647894\/ljad388.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/3\/382\/56690160\/ljad388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/3\/382\/56690160\/ljad388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T08:49:44Z","timestamp":1708159784000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/3\/382\/7308529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,12]]},"published-print":{"date-parts":[[2024,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad388","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,10,12]]}}}